Healthcare Weekly News and Deals –June 15^th, 2026

1. Danaher Corporation (NYSE: DHR) has completed its acquisition of Masimo Corporation (NASD: MASI), a leading patient monitoring company, for a total enterprise value of approximately $9.9 billion in cash Danaher (NYSE: DHR) completed its acquisition of Masimo (NASDAQ: MASI) on June 10, 2026, paying $180 per share in cash — a deal valued at roughly $9.9 billion including assumed debt and net of acquired cash. The transaction, which represents approximately 18x estimated 2027 EBITDA, adds Masimo’s industry-leading pulse oximetry and specialty diagnostics portfolio to Danaher’s Diagnostics segment. Danaher expects the acquisition to generate more than $530 million in Masimo EBITDA in 2027 and has targeted over $125 million in annual cost synergies and $50 million in annual revenue synergies by the fifth post-close year, funded through cash on hand and debt proceeds. (Link)
2. GSK plc (NYSE: GSK) has entered into a definitive agreement to acquire Nuvalent, Inc. (NASD: NUVL), a precision oncology biotech with two late-stage non-small cell lung cancer candidates currently under FDA review, for $10.6 billion in cash. GSK plc announced on June 9, 2026 a definitive agreement to acquire Cambridge, Massachusetts-based Nuvalent (NASDAQ: NUVL) for $124 per share in cash — a 40% premium to last close and aggregate equity consideration of $10.6 billion, or approximately $9.4 billion net of acquired cash. The acquisition centers on two late-stage assets under active FDA review: zidesamtinib (ROS1-positive NSCLC) and neladalkib (ALK-positive NSCLC), both of which could launch by year-end 2026 and are projected to generate combined revenues exceeding $800 million by 2029. (Link)
3. Chiesi Group has completed its approximately $1.9 billion acquisition of KalVista Pharmaceuticals, Inc. (NASD: KALV), adding EKTERLY® (sebetralstat) — the first and only oral, on-demand treatment for hereditary angioedema — to its Rare Diseases business unit. Chiesi Group, the Parma, Italy-based research-focused biopharmaceutical group, completed its acquisition of KalVista Pharmaceuticals (NASDAQ: KALV) on June 11, 2026, paying $27.00 per share in cash following a tender offer in which approximately 77.8% of shares were validly tendered, for aggregate consideration of approximately $1.9 billion. With the closing, Chiesi assumes ownership of EKTERLY® (sebetralstat), a plasma kallikrein inhibitor approved in the U.S., EU, UK, and Japan for the treatment of acute hereditary angioedema (HAE) attacks in patients aged 12 and older. (Link)
4. Novanta Inc. (NASD: NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a category leader in minimally invasive surgical consumables, from Arlington Capital Partners for $1.2 billion in upfront cash plus a $250 million milestone payment Novanta (NASDAQ: NOVT) struck a deal to acquire Riverpoint Medical from Arlington Capital Partners, a Washington D.C.-area private investment firm, for $1.2 billion upfront and up to $250 million in milestone payments due in Q1 2027 — implying a total potential consideration of $1.45 billion. The acquisition is priced at approximately 19x Riverpoint’s estimated 2026 Adjusted EBITDA and is expected to immediately accrete to Novanta’s 2026 adjusted EPS. Strategically, the deal doubles Novanta’s recurring medical consumables revenue to roughly $300 million and lifts medical end-market exposure to approximately 60% of total revenue, with Novanta financing the deal via cash on hand, a $300 million equity raise, and existing credit facilities. (Link)
5. Humana Inc. (NYSE: HUM) has signed a definitive agreement to divest all or substantially all of its approximately 40% minority interest in Gentiva, the nation’s largest hospice and palliative care provider, to a consortium of investors for approximately $900 million. Humana (NYSE: HUM) announced on June 10, 2026 a definitive agreement to sell substantially all of its minority interest in Gentiva — the nation’s leading hospice and end-of-life services provider operating more than 430 locations across 35 states — to an undisclosed consortium of investors for approximately $900 million. Proceeds will be directed to general corporate purposes. Closing is expected in Q3 2026, subject to regulatory approvals and customary conditions. (Link)
6. Medtronic plc (NYSE: MDT) has completed its acquisition of Scientia Vascular, a privately-held neurovascular access device maker, for $550 million with potential additional earn-out and milestone payments Medtronic (NYSE: MDT) completed its acquisition of Salt Lake City-based Scientia Vascular in June 2026 for $550 million — a deal originally signed in March 2026. Scientia’s portfolio of advanced guidewires and catheters is designed to improve physician navigation through complex cerebral vasculature, and will integrate seamlessly into Medtronic’s existing neurovascular product line to support full procedural workflows for stroke and neurovascular interventions. With approximately 310 employees, Scientia represents Medtronic’s latest strategic neurovascular investment, following similar sector consolidation plays by Boston Scientific and Stryker. (Link)
7. Keenova Therapeutics plc has agreed to sell its Percocet and Endocet opioid prescription drug businesses to Par Health, Inc. for total consideration of approximately $250 million, fully exiting the opioid market upon close. Keenova Therapeutics plc announced on June 13, 2026 a purchase agreement with Par Health, Inc. to divest its Percocet (oxycodone HCl/acetaminophen) and Endocet branded prescription opioid businesses for total consideration of approximately $250 million — comprising a $25 million upfront payment, subject to customary adjustments, plus quarterly earnout payments based on the gross profit of the divested business over a five-year period post-close. The transaction is expected to close in Q3 2026, subject to HSR antitrust clearance and customary closing conditions. Following the completion of all related obligations, Keenova will no longer market, manufacture, or distribute opioid products, representing a full strategic exit from the category. The divestiture allows Keenova to refocus capital allocation on its core non-opioid pipeline priorities. (Link)
8. Adial Pharmaceuticals, Inc. (NASD: ADIL) has acquired Azora Therapeutics, Inc. and its lead colon-targeted ulcerative colitis candidate AT177, concurrent with a private placement of up to $64 million led by Coastlands Capital. Adial Pharmaceuticals (NASDAQ: ADIL) announced on June 11, 2026 the acquisition of Azora Therapeutics in a stock exchange transaction, adding Azora’s lead asset AT177 — a proprietary oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist in IND-enabling studies for ulcerative colitis — as the combined company’s primary pipeline focus. Concurrent with the acquisition, Adial entered into a private placement of up to $64 million: $32 million upfront, led by Coastlands Capital, with a potential additional $32 million tranche tied to clinical milestones. Following shareholder approval and securities conversion, former Azora shareholders are expected to own approximately 51% of the combined company, financing investors approximately 41.3%, and existing Adial shareholders approximately 7.7%. Adial shares rose approximately 35% on announcement. (Link)
9. Sagility (NSE: SAGILITY) has acquired CareSeed, a Kansas City-based healthcare analytics company specializing in HEDIS quality reporting and Medicare Advantage performance, for up to approximately $30 million. Sagility, a tech-enabled healthcare operations company backed by institutional investors, acquired CareSeed in a deal valued at up to $30 million — comprising $17.5 million upfront and up to $12.5 million in earn-outs tied to performance. Founded in 2012 and based in Kansas City, Missouri, CareSeed serves 30 small and mid-sized U.S. payers through its cloud-native Forecast and Harvest platforms, generating $5.1 million in CY25 revenue at a 31.4% EBITDA margin. The acquisition is expected to be immediately EPS accretive to Sagility and adds 28 new Medicare Advantage health plan relationships, positioning Sagility to deliver an end-to-end quality operations continuum from HEDIS abstraction to prospective care gap closure. (Link)
10. SK Capital Partners-backed Spectrum Vascular has acquired Piccolo Medical, developer of 510(k)-cleared proprietary blood-flow sensing catheter guidance technology, to deepen its vascular access platform and accelerate commercialization of the Nav+ Stylet. Spectrum Vascular, a White Plains, New York-based vascular access and medication management products company backed by SK Capital Partners, announced on June 11, 2026 the acquisition of Piccolo Medical, a developer of next-generation catheter guidance products more than a decade in development. Piccolo’s real-time catheter guidance uses proprietary blood-flow sensing technology to precisely guide catheter tip placement, eliminating the need for confirmatory chest X-rays — a standard and costly step in most vascular access procedures. Piccolo completed its first successful patient placements of the Nav+ Stylet in May 2026. Augustus Shanahan, CEO of Piccolo, will join Spectrum alongside his team to advance development and commercialization. (Link)
11. Vizient has acquired Empierus, a healthcare-focused IT contracting and cost optimization advisory firm, to expand its indirect spend management capabilities across a sector spending more than $55 billion annually on information technology. Vizient, the Irving, Texas-based provider-driven healthcare performance improvement company with a $156 billion annual purchasing portfolio, announced on June 11, 2026 the acquisition of Empierus, a healthcare advisory firm specializing in IT contracting, healthcare technology management, and cost optimization. Through an existing partnership, Empierus delivered more than $36 million in savings for Vizient clients in 2025 alone; Empierus employees will join Vizient’s team of more than 250 indirect spend and purchased services experts. The acquisition addresses a rapidly growing, largely unmanaged category as healthcare organizations expand IT investments in cybersecurity, cloud, AI, and digital transformation. (Link)
12. Capsa Healthcare, backed by Francisco Partners, has acquired The Harloff Company, a leading manufacturer of healthcare storage and mobility products, for undisclosed terms to deepen its clinical workflow solutions portfolio Canal Winchester, Ohio-based Capsa Healthcare — acquired by private equity firm Francisco Partners in April 2026 for approximately $500 million — has made its first add-on acquisition by purchasing The Harloff Company, a 75-year-old manufacturer of medical storage cabinets, procedure carts, medication storage systems, and endoscopic processing solutions. The combination integrates Harloff’s durable clinical infrastructure with Capsa’s tech-enabled pharmacy automation and point-of-care platforms, creating a more comprehensive healthcare equipment offering for hospitals, ambulatory surgery centers, and long-term care facilities. (Link)
13. Grant Avenue Capital-backed PatientCare EMS Solutions has partnered with Superior Mobile Health, a Texas-based provider of non-emergency medical transportation services, expanding its geographic footprint into the Texas market PatientCare EMS Solutions, a New York-headquartered ground-based healthcare transportation platform backed by private equity firm Grant Avenue Capital, announced a strategic partnership with Superior Mobile Health, a San Antonio, Texas-based provider founded in 2011. Superior completed more than 80,000 patient transports in 2025 across a network of over 300 clinical staff, with strong existing relationships with Texas hospitals, municipalities, and nursing facilities. The partnership gives Superior access to PatientCare’s capital resources, operational infrastructure, fleet technology, and scale — and marks PatientCare’s entry into the Texas market under its buy-and-build strategy with Grant Avenue as sponsor. Terms were not disclosed. (Link)
14. Alembic Therapeutics, LLC has acquired NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved single-dose prescription treatment for bacterial vaginosis, from Exeltis USA, Inc. to expand its women’s health portfolio. Bedminster, New Jersey-based Alembic Therapeutics announced on June 9, 2026 the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc., assuming full U.S. commercialization and distribution responsibilities. NUVESSA is an FDA-approved, single-dose, pre-filled disposable applicator indicated for the treatment of bacterial vaginosis in females aged 12 and older — the most common vaginal infection in women of childbearing age, affecting an estimated 21 million U.S. women annually. (Link)
15. Chambers Home Health & Hospice, a Northeast Texas home-based care provider founded in 2002, has partnered with Lucent Health Group. Chambers Home Health & Hospice, a Melissa Chambers-founded provider of skilled home health and hospice services across more than 20 counties in Northeast Texas operating through three agencies — Chambers Home Health, Chambers Hospice, and Healthcare Associates LLC — announced on June 10, 2026 a partnership with Lucent Health Group (LHG). The transaction positions Chambers to build on over two decades of regional growth while accessing LHG’s capital resources and healthcare operating expertise to support continued expansion across a growing home-based care market. Cross Keys Capital served as exclusive financial advisor to Chambers; Calhoun, Bhella & Sechrest provided legal counsel. (Link)
16. Gemspring Capital ($5.1 billion AUM) has acquired Freedom Senior Services, a multi-state provider of culturally responsive home care, adult day, IDD, and VA services across Kentucky, Indiana, Ohio, Pennsylvania, and Tennessee Gemspring Capital Management, LP, a Westport, Connecticut-based middle market private equity firm with $5.1 billion of capital under management, acquired Freedom Senior Services, a provider of culturally responsive home care, adult day, intellectual and developmental disability (IDD), and VA services operating across Kentucky, Indiana, Ohio, Pennsylvania, and Tennessee. The transaction, announced in June 2026, was advised by Livingstone Partners on behalf of Gemspring. Freedom’s multilingual care delivery model and regional concentration in the Midwest and Appalachian markets positions it as a differentiated platform within a fragmented home- and community-based services sector facing strong demographic tailwinds. (Link)
17. Apex Paramedics has been sold to Royal Ambulance, a California-based medical transportation provider, in a transaction advised by Helix Health Capital Advisors, marking Royal’s entry into the Colorado market. Helix Health Capital Advisors served as exclusive financial advisor to Apex Paramedics, a Denver-based provider of scheduled non-emergent interfacility transport (IFT) services, in its sale to Royal Ambulance announced June 9, 2026. Founded in 2015, Apex serves the Denver metro and Colorado Springs markets under multi-year service agreements with leading health systems. Royal Ambulance, a California-based provider of medical transportation and specialty transport services across the San Francisco Bay Area, expands its geographic footprint beyond Northern California through the acquisition and gains a scalable IFT platform in a high-growth Colorado market. (Link)
18. 10x Genomics, Inc. (NASD: TXG) has acquired Proteintech Genomics, a division of Proteintech Group, to expand its proteomics and single-cell multiomic capabilities. 10x Genomics (NASDAQ: TXG) announced on June 9, 2026 the acquisition of Proteintech Genomics, a division within Proteintech Group, adding its Human Discovery Panel — the largest antibody-based single-cell protein panel currently available — designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles within sequencing-compatible workflows on 10x’s Chromium Flex chemistry. The acquisition is strategically timed to complement 10x’s April 2026 launch of the Atera whole-transcriptome single-cell platform, advancing the company’s multiomic vision by bridging proteomic and transcriptomic layers at single-cell resolution.  , and 10x Genomics stated the transaction will not meaningfully impact its near-term financial outlook. (Link)
19. AMN Healthcare Services (NYSE: AMN) has acquired Jaide Health, a Boston-based AI-enabled medical interpretation and translation startup, for undisclosed terms to expand language access solutions across the patient journey AMN Healthcare Services (NYSE: AMN) acquired Jaide Health through its Language Services division in June 2026 to pair AI-assisted language tools with AMN’s existing human interpreter network. Jaide Health’s platform provides real-time, AI-enabled support for routine verbal exchanges and written translations — such as patient intake and discharge communications — addressing language access gaps for Limited English Proficiency (LEP) patients outside clinical encounters. The acquisition is consistent with AMN’s broader strategy of deploying technology solutions that reduce friction across the care continuum. (Link)
20. PartsSource, a leading clinical technology performance platform, has acquired SkillNet, a healthcare workforce intelligence platform for hospital technology management teams, for undisclosed terms. Cleveland, Ohio-based PartsSource announced on June 9, 2026 the acquisition of SkillNet, a Workforce Intelligence platform purpose-built for healthcare technology management (HTM) departments. SkillNet provides hospitals and health systems with real-time visibility into technician competency compliance, skill-gap assessment, and team capability tracking — enabling HTM leaders to close critical technician deficiencies and expand care capacity. The acquisition extends PartsSource’s Enterprise Clinical Technology platform beyond parts procurement, service optimization, and asset performance management into the workforce intelligence layer, creating a more comprehensive operating system for hospital biomed and clinical engineering departments. (Link)
21. Chinook Investment Partners has made a growth equity investment in PractiVet, a Scottsdale, Arizona-based veterinary infusion and syringe pump device company, with debt financing support from Mercantile Bank. Chinook Investment Partners, a Castle Pines, Colorado-based private equity firm focused on healthcare and business services, completed a growth investment in PractiVet in April 2026 through a transaction supported by Mercantile Bank. Founded in 2007 and headquartered in Scottsdale, Arizona, PractiVet is a leading branded supplier of infusion and syringe pump devices and IV infusion consumables serving thousands of veterinary hospitals and universities nationwide, with more than 30,000 devices deployed across specialty, emergency, and academic settings. The deal is consistent with Chinook’s strategy of backing profitable, growth-stage companies in recession-resilient healthcare end markets with revenues between $5 million and $100 million and EBITDA between $1 million and $10 million. (Link)

Venture Deals and Other

1. Vida Ventures has led an oversubscribed $125 million Series B investment in SonoThera, with participation from ARK Invest, Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures SA, CureDuchenne Ventures, Vivo Capital, SymBiosis, and a roster of prominent existing investors to advance ultrasound-mediated nonviral genetic medicines. Vida Ventures led a highly syndicated $125 million Series B in South San Francisco-based SonoThera, joined by new investors ARK Invest (NYSE: ARKK), Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures, CureDuchenne Ventures, Vivo Capital, and SymBiosis, alongside returning backers including ARCH Venture Partners, Alexandria Venture Investments, Illumina Ventures, Johnson & Johnson Innovation – JJDC, RA Capital, Duquesne Family Office, Medical Excellence Capital, and Vertex Ventures HC. The oversubscribed round will advance SonoThera’s lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic, with the first DMD trial targeted for 2027. SonoThera’s proprietary RIPPLE™ ultrasound delivery and PORE™ payload engineering platforms represent a novel nonviral alternative to traditional gene therapy. (Link)
2. Viking Global Investors has led an oversubscribed $100 million Series E financing in GT Medical Technologies, with participation from MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures, to accelerate commercialization of its GammaTile brain tumor radiotherapy platform. Viking Global Investors — a global investment firm managing over $52 billion in assets — led an oversubscribed $100 million Series E in Tempe, Arizona-based GT Medical Technologies, joined by re-upping investors MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The round follows compelling Phase 3 ROADS trial data presented at ASCO 2026 showing GammaTile — the company’s FDA-cleared bioresorbable radiation implant — reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard of care. Proceeds will fuel commercial and operational expansion and support the BRIDGES RCT in glioblastoma patients. This round follows a $53 million Series D completed in 2025. (Link)
3. Atlas Venture and Medicxi Ventures have co-led a combined $101 million Series A and Series B financing in Ethyreal Bio, an ophthalmic biotech emerging from stealth to develop a first-in-class IGF-1R inhibitor for thyroid eye disease and Graves’ disease. Ethyreal Bio emerged from stealth on June 10, 2026 with $101 million in combined financing — a Series A co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital, followed by a Series B led by Avoro Capital with all Series A investors participating. The company’s lead asset, ETHY-001, is a first-in-human candidate targeting the insulin-like growth factor 1 receptor (IGF-1R) for thyroid eye disease (TED) and Graves’ disease, entering a market currently anchored by Amgen’s Tepezza (teprotumumab), which generated over $2 billion in peak annual sales. Proceeds will fund ETHY-001 into Phase 1, planned for later in 2026, with a differentiated mechanism targeting potential improvements in tolerability versus the current standard of care. (Link)
4. Prime Radiant Partners has invested $50 million in Cellares, the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, growing its Series D to $327 million and bringing total capital raised to $739 million. Cellares, the South San Francisco-based IDMO pioneering automated cell therapy manufacturing, announced on June 15, 2026 a $50 million investment from Prime Radiant Partners, growing its Series D financing — originally anchored by BlackRock and Eclipse — to $327 million total, with total capital raised reaching $739 million. The new capital supports Cellares’ global Smart Factory buildout spanning South San Francisco, Bridgewater (NJ), Leiden (Netherlands), and Kashiwa City (Japan), targeting commercial-scale production in 2027. Cellares has manufactured and delivered the first GMP doses of Cabaletta Bio’s investigational CAR-T therapy on its Cell Shuttle® platform, signed a 10-year supply agreement with Cabaletta, and secured a $380 M global manufacturing agreement with Bristol Myers Squibb for commercial-scale cell therapy capacity. (Link)
5. Caffeinated Capital has led an oversubscribed $23 million Series A investment in Neion Bio, with participation from Basis Set Ventures and other new investors, to advance the company’s egg-based biologics manufacturing platform. Caffeinated Capital, an early-stage technology-focused fund and original seed backer of Neion Bio, led the New York-based biotech’s oversubscribed $23 million Series A, with new investors including Basis Set Ventures, Clocktower Ventures, and Hawktail also joining the round. Neion Bio deploys frontier genetic engineering to convert chicken eggs into highly efficient biological manufacturing vessels for complex, glycosylated proteins — positioning the company as an infrastructure-layer alternative to traditional cell culture-based biologic production. The financing follows Neion’s March 2026 emergence from stealth and its announcement of a commercial co-development and supply agreement with a major pharmaceutical company for a multi-product biosimilars collaboration. (Link)
6. Tau Ventures, Upstream Ventures, Proofpoint Capital, Draper Associates, Wicklow Capital, and 29 additional investors have co-invested in a $24 million Series A round in Klinic Inc., a Texas-based specialty healthcare provider-enablement platform. Klinic Inc., a Frisco, Texas-based healthcare technology company, closed a $24 million equity financing round backed by 34 investors — including Tau Ventures, Upstream Ventures, Proofpoint Capital, Draper Associates, and Wicklow Capital. Founded in 2021 by Avish Bhama and Dan Cheung, Klinic operates as a Shopify-like infrastructure layer for independent specialty practices across 12 medical disciplines including oncology, cardiology, and rare diseases, providing unified tools for patient acquisition, EHR, RCM, prior authorization tracking, and care coordination. The company’s first round sale closed in January 2026 per an SEC Form D filing, and proceeds are expected to fund aggressive platform expansion across North American specialty markets. (Link)
7. Shore Search Partners has led a Series A growth investment in Aton Health, a Kansas City-based healthcare company embedding research infrastructure into routine specialty care to generate real-world evidence at scale. Aton Health, based in Kansas City, Missouri, announced on June 12, 2026 the closing of a Series A growth investment led by Shore Search Partners, the healthcare-focused venture arm of Shore Capital Partners — which closed $850 million across two new funds in 2025. Aton integrates its TrialSight™ and CareSight™ data collection platforms directly into existing specialty practices, enabling providers to participate in non-interventional research programs — beginning in gastroenterology and expanding into additional specialties — without disrupting clinical workflows. The model connects pharmaceutical sponsors with high-quality, real-world patient populations at the point of care, addressing structural limitations of traditional clinical trial site access. Investment amount was not disclosed. (Link)
8. Index Ventures has led a €6 million ($7 million) seed round in Uncovr, a Paris- and New York-based surgical AI startup, with participation from Seedcamp, Frst, No Label Ventures, Entrepreneurs First, and notable healthcare angels, to build AI infrastructure that converts surgical video into clinical records. Index Ventures — one of Europe’s most active technology venture funds — led the debut seed round in Uncovr, joined by institutional backers Seedcamp, Frst, No Label Ventures, and Entrepreneurs First, as well as angel investors including Digital Surgery founder Jean Nehme (whose prior company was acquired by Medtronic (NYSE: MDT)), Color Health CEO Othman Laraki, and Meta board member Charlie Songhurst. Uncovr’s AI platform analyzes real-time surgical and endoscopic video to automatically generate operative reports and procedural billing codes, addressing a structural documentation gap affecting more than 400 million surgeries annually. The company plans to use the capital to scale its AI platform and expand into U.S. hospital systems. (Link)
9. NVENTRIC, a South Korean medical device company specializing in vascular intervention, has closed a ₩34.5 billion (~$22.6 million) pre-IPO financing round from 14 institutional investors, including Loftyrock Investment, Moneyball Ventures, Shinhan Capital, IPS Ventures, and LB Investment, to fund global expansion and a planned KOSDAQ listing. NVENTRIC attracted 14 new institutional backers to its pre-IPO round, with Shinhan Capital, IPS Ventures, Quad Asset Management, and Heungkuk Securities participating as follow-on investors from prior rounds alongside new commitments from Loftyrock Investment, Moneyball Ventures, Moneyball Partners, Scale-up Partners, AJU IB Investment, HB Investment, Pacific Capital, Flexus Partners, and Heungkuk Securities. The company has achieved a 52.9% CAGR in cumulative revenue over the past four years, posting approximately $3.9 million in total revenues through the period. Proceeds from the round will fund global commercial expansion and accelerate NVENTRIC’s preparations for a KOSDAQ IPO. (Link)
10. Institutional healthcare investors and company insiders have participated in a $10.5 million private placement financing in CervoMed Inc. (NASD: CRVO), a clinical-stage biotech developing treatments for age-related neurological disorders. CervoMed (NASDAQ: CRVO) raised $10.5 million in a private placement led by institutional healthcare investors, with meaningful insider co-investment from board chairman Joshua S. Boger, Ph.D. — founder of Vertex Pharmaceuticals (NASDAQ: VRTX) — alongside trusts affiliated with CEO Dr. John Alam and board member Sylvie Grégoire. The company sold 3,360,377 units at $3.14 per unit, with Series B and C warrants that could generate an additional $21.7 million in gross proceeds if fully exercised. Proceeds will fund ongoing development of neflamapimod, an oral neuroinflammation inhibitor being advanced toward Phase 3 for dementia with Lewy bodies, while supporting pursuit of a strategic partnership, and are expected to extend CervoMed’s cash runway into Q2 2027. (Link)
11. Arcadia Biosciences (NASD: RKDA) has raised $4 million through an at-the-market private placement of common stock and preferred investment options under Nasdaq rules to fund working capital and general corporate purposes. Arcadia Biosciences (NASDAQ: RKDA), a Dallas-based producer and marketer of wellness products including its Zola coconut water brand, completed a $4 million private placement priced at $1.03 per share on June 12, 2026, issuing 3,883,496 common shares with accompanying Series A-1 and A-2 preferred investment options exercisable at $0.91 per share. Investors attracted to RKDA’s at-the-market structure, which bypasses shareholder approval requirements under Nasdaq Rule 7.1 provisions, drove a notable 18%+ single-day stock price surge on the announcement. Proceeds will be directed toward working capital needs and general corporate operations as the company continues executing on its consumer wellness portfolio strategy. (Link)
12. Institutional investors have participated in an $8.5 million private placement in Bluejay Diagnostics (NASD: BJDX), a Massachusetts-based near-patient testing company, with total potential proceeds of up to $23.7 million if warrants are fully exercised. Bluejay Diagnostics (NASDAQ: BJDX), headquartered in Acton, Massachusetts, closed an $8.5 million private placement on June 5, 2026, issuing 3,655,917 shares at $2.325 per share alongside two series of warrants — Series G (exercisable for five years) and Series H (short-term) — each covering up to 3,655,917 additional shares at a $2.075 exercise price. If warrants are fully exercised, total gross proceeds could reach approximately $23.7 million, which BJDX estimates would extend its cash runway well beyond its anticipated FDA approval and first full year of commercialization. Near-term proceeds are targeted toward clinical studies supporting regulatory clearance and R&D activities. (Link)
13. New and existing institutional and sophisticated investors have collectively committed A$30 million to Vitrafy Life Sciences (ASX: VFY) through a non-underwritten institutional placement to fund manufacturing expansion and accelerate U.S. market entry for its Guardion cryopreservation devices. Vitrafy Life Sciences (ASX: VFY), an Australian life sciences company focused on smart cryopreservation solutions, secured firm commitments for a A$30 million (~US$19.5 million) institutional placement on June 10, 2026, issuing approximately 11.54 million new shares at A$2.60 per share — a 31.6% discount to its last closing price. The capital raise is directed toward three key uses: A$15 million for Guardion device fleet inventory build, A$8 million for U.S. sales and operational scaling, and A$5.2 million for working capital. The placement, backed by both new and existing institutional backers, supports Vitrafy’s positioning ahead of the 2027 blood industry replacement cycle in the U.S., where the company has partnered with Vitalant for frozen red blood cell preservation solutions. (Link)

Market Rumors

1. Matt Holt’s Thoreau Group, backed by Apollo Global Management, is reported to be in advanced talks to acquire Ensemble Health Partners, a leading revenue cycle management company, in a deal valuing the business at approximately $12 billion. Bloomberg reported on June 12, 2026 that Thoreau Group — the healthcare technology platform created by former New Mountain Capital managing director and president Matt Holt, backed by Apollo Global Management — is in advanced talks to acquire Ensemble Health Partners and that a deal could be signed imminently. Cincinnati-based Ensemble Health Partners is one of the largest revenue cycle management companies in the U.S., generating approximately $2.7 billion in annual revenues serving major health systems. Thoreau Group is expected to become the controlling shareholder of Ensemble. The reported valuation of approximately $12 billion would represent one of the largest healthcare services transactions of 2026. No parties have confirmed the report. This item is based solely on Bloomberg reporting and should be treated as unconfirmed pending an official announcement. (Link)